Brain metastases often occur as a result of advanced cancer, and despite medical innovations, are still associated with a ...

Scientists from Institut Curie, the CNRS, and Inserm have just created a novel class of molecules capable of destroying ...

Panelists discuss how the EMERALD trial demonstrated elacestrant's efficacy in ESR1-mutated tumors, particularly in patients who had received CDK4/6 inhibitors for at least 12 months. This led to its ...

In a new study led by the UCLA Health Jonsson Comprehensive Cancer Center, investigators show that using advanced MRI imaging ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for ...